

# 60-Day PNS Treatment Enables Identification of Delayed Responders and Non-Responders

Li S, MD<sup>1</sup>, Naidu R, MD<sup>2</sup>, Desai MJ, MD<sup>3</sup>, Sheth S, MD<sup>4</sup>, Crosby ND, PhD<sup>5</sup>, Boggs JW, PhD<sup>5</sup>

<sup>1</sup>Premier Pain Centers, Shrewsbury, NJ; <sup>2</sup>California Orthopedics & Spine, Larkspur, CA; <sup>3</sup>ISPPC, Washington, DC;

<sup>4</sup>Sutter Roseville Pain Management, Roseville, CA; <sup>5</sup>SPR Therapeutics, Cleveland, OH



## BACKGROUND

- Conventional neurostimulation for pain relief in the United States typically involves either no trial or a brief (e.g., ~7-day) trial to assess patient responsiveness.
- Low real-world trial conversion rates (41-65%) and lack of efficacy following implantation as a leading cause of system explant suggest that improved patient identification strategies are needed.<sup>1-5</sup>
- A novel percutaneous PNS system has demonstrated that treatment over a 60-day period may obviate the need for a permanently implanted system altogether in some patients by providing long-term relief.<sup>6-13</sup>
- A 60-day treatment period may also facilitate a more detailed evaluation of the patient response over time to better identify delayed responders and non-responders to neurostimulation therapies.



## METHODS

- Anonymized real-world treatment data were compiled from patients that previously underwent implantation of temporary percutaneous leads and opted-in to provide real-world data to the device manufacturer
- Patient reports of percent pain relief were collected in-person or by phone during routine interactions with device representatives as-needed throughout the 60-day treatment (e.g., for device support, programming)
- Inclusion in the analysis required:
  - at least one report of percent pain relief within the first 14 days of treatment;
  - at least two reports total during the 60-day treatment.
- Responder =  $\geq 50\%$  pain relief



## RESULTS & DISCUSSION

- A total of 675 anonymized patient records were identified for inclusion, including 4091 individual reports (an average of 6.1 reports per patient from baseline through the end of the 60-day treatment).



- 36.5% of patients changed from non-responder to responder or vice versa before the end of the 60-day treatment period.
- Delayed responders did not reach their maximum mean pain relief and delayed non-responders did not reach their minimum mean pain relief until the final two weeks of the 60-day treatment.

- 60-day treatment may help identify delayed responders, providing the opportunity for sustained relief and improving access to effective PNS treatment that would likely have been deemed ineffective when a short trial period is used.**
- 60-day treatment may also improve delayed non-responder identification whose favorable responses wane over time.**
- These scenarios support the notion of a prolonged temporary stimulation period, ideally for up to 60 days, to help inform PNS treatment strategies that may optimize patient outcomes while reducing cost and invasiveness.**

1. Huang et al., 2015; 2. Murphy et al., 2017; 3. van Buyten et al., 2017; 4. Pope et al., 2017; 5. Dupre et al., 2018; 6. Wilson et al., 2014a; 7. Wilson et al., 2014b; 8. Rauck et al., 2014; 9. Gilmore et al., 2019; 10. Gilmore et al., 2020; 11. Gilmore et al., 2021; 12. Deer et al., 2021a; 13. Deer et al., 2021b

Support for this study was provided by SPR Therapeutics. RN, SL, and MD are consultants to SPR Therapeutics. NC and JB are employees of SPR Therapeutics.